Trial Profile
A phase II study to evaluate docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Dec 2015 New trial record